Holen Sie sich die Stockscreener-App
2.68
1.47%
-0.04
Vorhandelsmarkt:
2.72
0.04
+1.49%
Schlusskurs vom Vortag:
$2.72
Offen:
$2.71
24-Stunden-Volumen:
30,709
Relative Volume:
0.23
Marktkapitalisierung:
$3.84M
Einnahmen:
Nettoeinkommen (Verlust:
$-28.53M
KGV:
-1.5052
EPS:
-1.7805
Netto-Cashflow:
$-20.10M
1W Leistung:
-21.87%
1M Leistung:
-67.32%
6M Leistung:
-84.19%
1J Leistung:
-97.75%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$2.55
$3.61
52-Wochen-Spanne:
$1.865
$139.00
Medicus Pharma Ltd Stock (MDCX) Company Profile
Firmenname
Medicus Pharma Ltd
Sektor
Telefon
610-540-7515
Adresse
300 CONSHOHOCKEN STATE RD., W. CONSHOHOCKEN
Compare MDCX vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MDCX
Medicus Pharma Ltd
|
2.68 | 3.84M | 0 | -28.53M | -20.10M | -1.7805 |
LLY
Lilly Eli Co
|
1,270.75 | 1.13T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
257.78 | 621.22B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
284.80 | 503.28B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
149.88 | 369.78B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
153.93 | 292.58B | 54.66B | 13.58B | 16.05B | 7.0171 |
Medicus Pharma Ltd Aktie (MDCX) Neueste Nachrichten
Form PRE 14A MEDICUS PHARMA LTD. For: 19 October By Investing.com - Investing.com South Africa
Form PRE 14A MEDICUS PHARMA LTD. For: 19 October By Investing.com - Investing.com UK
409,411 directly owned shares are only part of an amended Medicus Pharma (MDCX) stake report. - Stock Titan
Medicus Pharma Warrant (MDCXW) Jumps 66.67% to $0.20 as Buyers Probe Upper RangePut Flow Alert - https://www.dars.gov.et/
The FDA authorized a planned skin-cancer study for people with a rare inherited condition. - Stock Titan
Medicus Pharma (MDCX) Shares Fall 24% After Hours: Here's Why - Benzinga
Medicus Pharma to implement 50-for-1 share consolidation to meet Nasdaq minimum bid - TradingView
Medicus Pharma to execute 50-to-1 reverse stock split on Oct. 12 - StreetInsider
Medicus Pharma Ltd. Warrant (MDCXW) Holds Flat at $0.35 Inside a Narrow Trading BandMACD Signal Stocks - https://www.dars.gov.et/
Medicus Pharma Warrant (MDCXW) Trades Flat at $0.35, Pinned Between $0.33 Support and $0.37 ResistanceProfit Surge Picks - https://www.siam.in/
Medicus Pharma Ltd. (MDCX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Dr. Raza Bokhari Discloses Investment at Medicus Pharma Ltd. with 5.3% Stake - TradingView
Medicus Pharma ends standby equity purchase agreement with Yorkville - Investing.com
How big is Medicus Pharma (MDCX) CEO Raza Bokhari's stake? - Stock Titan
MDCX 8-K FilingsMedicus Pharma Ltd. SEC 8-K - Stock Titan
FDA Clears Medicus SkinJect Study for Gorlin Syndrome - MyChesCo
Inside the deal: How a Montco biotech secured a Pfizer drug candidate - The Business Journals
Form 8K Medicus Pharma Ltd For: 11 September By Investing.com - Investing.com Nigeria
Medicus Pharma officers receive restricted shares in lieu of cash bonuses - Investing.com Nigeria
Medicus Pharma officers receive restricted shares in lieu of cash bonuses - Investing.com India
Medicus Pharma officers receive restricted shares in lieu of cash bonuses - Investing.com
Form 8K Medicus Pharma Ltd For: 11 September By Investing.com - Investing.com India
Medicus Pharma officers receive restricted shares in lieu of cash bonuses - Investing.com UK
Medicus Pharma officers receive restricted shares in lieu of cash bonuses - Investing.com
Medicus Pharma posts phase 2 study results for skin cancer drug By Investing.com - Investing.com Australia
Medicus Pharma officers receive restricted shares in lieu of cash bonuses By Investing.com - Investing.com South Africa
Medicus Pharma posts phase 2 study results for skin cancer drug - Investing.com Nigeria
Medicus Pharma secures Pfizer ADC deal, advances SkinJect and precision oncology strategy - Proactive financial news
Medicus Pharma secures Pfizer ADC deal, advances SkinJect and precision oncology strategy - Yahoo Finance
Medicus Pharma Identifies 200 µg SkinJect Patch as Lead Development Dose After Phase 2 Study - Yahoo Finance
Conshohocken's Medicus Pharma Picks Up a Discarded Pfizer Cancer Drug in a Deal Worth More Than $1 Billion - BioBuzz
Medicus Pharma posts phase 2 study results for skin cancer drug - Investing.com India
Medicus Pharma posts phase 2 study results for skin cancer drug - Investing.com Canada
Medicus Pharma Ltd. Posts Abridged Phase 2 Clinical Study Report for SkinJect® SKNJCT-003, Advances Gorlin Syndrome Development Plan - Quiver Quantitative
Medicus Pharma posts phase 2 study results for skin cancer drug - Investing.com UK
FDA authorizes the next study of a skin cancer patch - Stock Titan
Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company - BioBuzz
Medicus Pharma reports positive Phase 2 data for SkinJect in skin cancer treatment - Proactive financial news
Medicus Pharma (MDCX) grants COO 735K shares and options - Stock Titan
Medicus Pharma (NASDAQ: MDCX) awards stock and options to its chief medical officer - stocktitan.net
Medicus Pharma (MDCX) hands CSO 588K shares and 100K options - stocktitan.net
Medicus Pharma (MDCX) CEO adds millions of shares and options in 2026 grant - Stock Titan
CFO adds Medicus Pharma (MDCX) stock and options - stocktitan.net
Medicus Pharma Prioritises CD228V Oncology Programme in Development Strategy - Yahoo Finance
Medicus Pharma shifts focus to precision oncology with CD228V By Investing.com - Investing.com Nigeria
Medicus Pharma shifts focus to precision oncology with CD228V - Investing.com
Medicus Pharma shifts focus to precision oncology with CD228V By Investing.com - Investing.com UK
Medicus Pharma Ltd. Repositions as Precision Oncology-Led Biotech, Prioritizes CD228V, SkinJect and Teverelix Programs - Quiver Quantitative
Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company - Yahoo Finance
Medicus Pharma reorients around new cancer drug candidate, sharpens focus for other programs - Proactive financial news
Finanzdaten der Medicus Pharma Ltd-Aktie (MDCX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.19%
5.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):